BNT 116
Alternative Names: BNT-116Latest Information Update: 04 Jul 2025
At a glance
- Originator BioNTech
- Class Antineoplastics; Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 25 Apr 2025 Updated efficacy, adverse events and pharmacodynamics data from the LuCa-MERIT-1 phase I trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 07 May 2024 Safety and efficacy data from a phase I LuCa-MERIT-1 trial in non-small cell lung cancer released by BioNTech
- 05 Apr 2024 Efficacy, immunogenicity and adverse event data from the phase I LuCa-MERIT-1 trial in non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)